Combination high-dose omega-3 fatty acids and high-dose cholecalciferol in new onset type 1 diabetes: a potential role in preservation of beta-cell mass
Baidal DA, Ricordi C, Garcia-Contreras M, Sonnino A, Fabbri A
European review for medical and pharmacological sciences · 27 citations
Review labels
Neutral facts our review recorded about how this study was done. They describe method, never whether we like the result.
How it was studied
- Design
- Case report (indexed by PubMed)
- Studied in
- People
- Main outcome
- Health markers and function
Who paid for it
- Funding
- Funding not disclosed
Publication
- Published
- 2016-07-01 · Eur Rev Med Pharmacol Sci · vol. 20 · issue 15 · pp. 3313–8
- Publisher
- National Institutes of Health
- Cited
- 33 citations · more than 95% of similar papers · 4.2× the field average
- Impact
- Top 10% most cited in its field
- References
- 0 works
- Access
- Paywalled
- Research areas
- Diet, Metabolism, and Disease · Pancreatic function and diabetes · Diabetes and associated disorders
- Keywords
- Cholecalciferol, Vitamin D and neurology, Medicine, Internal medicine, Endocrinology, Diabetes mellitus, Vitamin, Type 2 diabetes, Type 1 diabetes, Randomized controlled trial, BETA (programming language), vitamin D deficiency
- MeSH
- b-lymphocytes, humans, diabetes mellitus, type 1, cholecalciferol, c-peptide, fatty acids, omega-3, hypoglycemic agents, treatment outcome, drug therapy, combination, immunity, cellular, dose-response relationship, drug, dietary supplements, adolescent, male
5 authors
From US, ES, IT
- David A. BaidalMiami Transplant Institute
- Camillo Ricordi
- Marta García-ContrerasUniversity of Miami; Valencia Catholic University Saint Vincent Martyr
- Alice SonninoMassachusetts College of Pharmacy and Health Sciences
- Andrea FabbriUniversity of Rome Tor Vergata
Abstract
Several studies have evaluated the role of inflammation in type 1 diabetes (T1D). The safety profile and anti-inflammatory properties of high dose omega-3 fatty acids combined with Vitamin D supplementation make this therapy a possible candidate for T1D intervention trials. Herein, we describe the case of a 14-year-old boy with new onset T1D treated with high dose Omega-3 and vitamin D3. By 12 months, peak C-peptide increased to 0.55 nmol/L (1.66 ng/mL) corresponding to a 20% increment from baseline and AUC C-peptide was slightly higher compared to 9 months (0.33 vs. 0.30 nmol/L/min) although remaining slightly lower than baseline. Combination high-dose Omega-3 fatty acids and high-dose vitamin D3 therapy was well tolerated and may have beneficial effects on beta-cell function. Randomized controlled trials could be of assistance to determine whether this therapy may result in the preservation of beta-cell function in patients with new onset T1D.
Abstract via Europe PMC. Copyright remains with the authors or publisher.
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.